Skip to main content

Advertisement

SpringerLink
Log in

PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The implications of Phosphatidylinositol 3-kinase (PIK3CA) mutations and its aberrant protein expression in breast cancer (BC) different molecular subtypes and patients’ outcome remain controversial. The aims of this study were to assess the prevalence and clinical significance of PIK3CA protein expression in BC and to determine its association with its different molecular classes. PIK3CA protein expression was assessed in a well-characterized series of early stage BC (n = 1,394) with long-term follow-up, using tissue microarrays and immunohistochemistry. Associations between PIK3CA expression and clinicopathological variables, molecular classes, and patients’ outcome were investigated. Positive PIK3CA expression was associated with poor prognostic variables including higher grade, larger size, nodal involvement, vascular invasion, and higher proliferative fraction (P < 0.001). Increased PIK3CA expression was associated with the basal-like breast cancer (BLBC) and HER2-positive classes as well as triple negative non-basal (TNnon-B) tumors (P < 0.001). The luminal class showed reduced PIK3CA expression relative to other classes. Patients with PIK3CA positive tumors had shorter BC specific and disease free survival, independent of other prognostic factors except grade. Similar associations with outcome were found when the analysis was restricted to the large luminal class of tumors. PIK3CA is an oncogenic biomarker associated with poor prognosis in BC. Although, PIK3CA over-expression was more prevalent in BLBC and HER2-positive tumors it appeared to be a marker of poor differentiation rather than of a particular subtype. Thus, targeting of PIK3CA using specific inhibitors could potentially be beneficial, particularly for patients with more aggressive poorly differentiated tumors, irrespective of their molecular subtype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657

    Article  CAS  PubMed  Google Scholar 

  2. Jiang B-H, Liu L-Z (2008) PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784:150–158

    CAS  PubMed  Google Scholar 

  3. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26:1338–1345

    Article  CAS  PubMed  Google Scholar 

  4. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619

    Article  CAS  PubMed  Google Scholar 

  5. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554

    Article  CAS  PubMed  Google Scholar 

  6. Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94:455–459

    Article  CAS  PubMed  Google Scholar 

  7. Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486–5496

    Article  CAS  PubMed  Google Scholar 

  8. Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA Gene in Ovarian and Breast Cancer. Cancer Res 64:7678–7681

    Article  CAS  PubMed  Google Scholar 

  9. Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102:802–807

    Article  CAS  PubMed  Google Scholar 

  10. Maira S-M, Stauffer F, Schnell C, García-Echeverría C (2009) PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 37:265–272

    Article  CAS  PubMed  Google Scholar 

  11. Gustin JP, Cosgrove DP, Park BH (2008) The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets 8:733–740

    Article  CAS  PubMed  Google Scholar 

  12. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13:408–414

    Article  CAS  PubMed  Google Scholar 

  13. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, Isola J, Bendahl P-O, Rosen N, Hibshoosh H, Ringner M, Borg A, Parsons R (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104:7564–7569

    Article  CAS  PubMed  Google Scholar 

  14. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13:6064–6069

    Article  CAS  PubMed  Google Scholar 

  15. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom P-O, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005) PIK3CA mutations correlate with hormone receptors node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554–2559

    Article  CAS  PubMed  Google Scholar 

  16. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772–775

    Article  CAS  PubMed  Google Scholar 

  17. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdes A, Gestraud P, Hupe P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T (2008) Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10:R101

    Article  PubMed  CAS  Google Scholar 

  18. Hoeflich KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15:4649–4664

    Article  CAS  PubMed  Google Scholar 

  19. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A (2006) PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 208:350–355

    Article  CAS  PubMed  Google Scholar 

  20. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y (2006) Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13:137–144

    Article  PubMed  Google Scholar 

  21. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350

    Article  CAS  PubMed  Google Scholar 

  22. Albasri A, Seth R, Jackson D, Benhasouna A, Crook S, Nateri AS, Chapman R, Ilyas M (2009) C-terminal Tensin-like (CTEN) is an oncogene which alters cell motility possibly through repression of E-cadherin in colorectal cancer. J Pathol 218:57–65

    Article  CAS  PubMed  Google Scholar 

  23. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721

    PubMed  Google Scholar 

  24. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495–506

    Article  CAS  PubMed  Google Scholar 

  25. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772–4778

    Article  PubMed  Google Scholar 

  26. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259

    Article  CAS  PubMed  Google Scholar 

  27. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874

    Article  CAS  PubMed  Google Scholar 

  28. Elston CW (2005) Classification and grading of invasive breast carcinoma. Verh Dtsch Ges Pathol 89:35–44

    CAS  PubMed  Google Scholar 

  29. Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AH (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45:1780–1787

    Article  CAS  PubMed  Google Scholar 

  30. Thompson JE, Thompson CB (2004) Putting the Rap on Akt. J Clin Oncol 22:4217–4226

    Article  CAS  PubMed  Google Scholar 

  31. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310

    Article  CAS  PubMed  Google Scholar 

  32. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084–6091

    Article  CAS  PubMed  Google Scholar 

  33. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15:1064–1069

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Queen’s Medical Centre, Clifton Boulevard, Nottingham, NG7 2UH, UK

    Mohammed A. Aleskandarany, Mohamed A. H. Ahmed, Desmond G. Powe, Ian O. Ellis & Andrew R. Green

  2. Pathology Department, Faculty of Medicine, Menoufyia University, Menoufyia, Egypt

    Mohammed A. Aleskandarany

  3. Department of Pathology, Nottingham University Hospitals NHS Trust, Nottingham, UK

    Emad A. Rakha & Emma C. Paish

  4. Breast Institute, Nottingham University Hospitals NHS Trust, Nottingham, UK

    R. Douglas Macmillan

  5. Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

    Mohamed A. H. Ahmed

Authors
  1. Mohammed A. Aleskandarany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emad A. Rakha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed A. H. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Desmond G. Powe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emma C. Paish
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Douglas Macmillan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ian O. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrew R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew R. Green.

Additional information

This study was approved by Nottingham Research Ethics Committee 2 under the title of “Development of a molecular genetic classification of breast cancer”.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aleskandarany, M.A., Rakha, E.A., Ahmed, M.A.H. et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122, 45–53 (2010). https://doi.org/10.1007/s10549-009-0508-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0508-9

Keywords

Search

Navigation